3D Printing via Melt Extrusion Deposition Facilitates the Use of Extended-Release Profiles in Preclinical Research and Development

Traditional methods for developing modified-release (MR) formulations involve numerous iterations and large quantities of drug substances, which pose considerable challenges in exploration settings. Given the growing necessity for modified-release (MR) formulations in the pharmaceutical industry, particularly during the preclinical research and development phase, modified-release strategies may serve as attractive alternatives to discontinuing clinical development and could mitigate the costs and time associated with identifying new drug candidates. This study specifically explores the application of melt extrusion deposition (MED) 3D printing technology as a rapid prototyping platform for creating extended-release (ER) oral dosage forms tailored for the preclinical phase. Using the model compound BI 894416, the study demonstrated that MED 3D printing enables precise control over drug release profiles through both structural and compositional designs. The physicochemical analysis conducted during the 3D printing process revealed no degradation or compatibility issues. <i>In vivo</i> pharmacokinetic (PK) studies in rats and dogs validated the extended-release (ER) performance of BI 894416, with <i>t</i><sub>max</sub> values of 2-4 h in rats and 5 h in dogs. The ER tablets achieved prolonged plasma exposure and reduced peak-to-trough fluctuations compared to those of immediate-release (IR) formulations (ER: 144 versus IR: 929 in dogs). A Level A <i>in vitro-in vivo</i> correlation (IVIVC) was established, demonstrating strong alignment between <i>in vitro</i> dissolution and <i>in vivo</i> absorption up to 4 h, with a minor lag time observed. These results further confirmed the likely absorption of BI 894416 in the upper gastrointestinal (GI) tract and the potentially ascending colon. These findings highlight the potential of MED 3D printing to streamline the development of MR formulations in preclinical settings, offering a flexible, efficient, and material-sparing alternative to conventional approaches.

Authors

Institutions

Publication Details

Journal
Molecular Pharmaceutics
Published
2025-08-11
DOI
https://doi.org/10.1021/acs.molpharmaceut.5c00413
Primary Topic
3D Printing in Biomedical Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

3D Printing via Melt Extrusion Deposition Facilitates the Use of Extended-Release Profiles in Preclinical Research and Development

Atsushi Sakurai, Simone M. Blattner, Georg Boeck, Sandra Frankenreiter et al.
Molecular Pharmaceutics
3D Printing in Biomedical Research
article

3D Printing via Melt Extrusion Deposition Facilitates the Use of Extended-Release Profiles in Preclinical Research and Development

Atsushi Sakurai, Simone M. Blattner, Georg Boeck, Sandra Frankenreiter, Achim Grube, Xianghao Zuo, Takuya Kikuchi, Jingyu Lu, Miao Jin, Gang Wang, Markus Metzger, Katsuyoshi Fujimoto
article en

Abstract

Traditional methods for developing modified-release (MR) formulations involve numerous iterations and large quantities of drug substances, which pose considerable challenges in exploration settings. Given the growing necessity for modified-release (MR) formulations in the pharmaceutical industry, particularly during the preclinical research and development phase, modified-release strategies may serve as attractive alternatives to discontinuing clinical development and could mitigate the costs and time associated with identifying new drug candidates. This study specifically explores the application of melt extrusion deposition (MED) 3D printing technology as a rapid prototyping platform for creating extended-release (ER) oral dosage forms tailored for the preclinical phase. Using the model compound BI 894416, the study demonstrated that MED 3D printing enables precise control over drug release profiles through both structural and compositional designs. The physicochemical analysis conducted during the 3D printing process revealed no degradation or compatibility issues. <i>In vivo</i> pharmacokinetic (PK) studies in rats and dogs validated the extended-release (ER) performance of BI 894416, with <i>t</i><sub>max</sub> values of 2-4 h in rats and 5 h in dogs. The ER tablets achieved prolonged plasma exposure and reduced peak-to-trough fluctuations compared to those of immediate-release (IR) formulations (ER: 144 versus IR: 929 in dogs). A Level A <i>in vitro-in vivo</i> correlation (IVIVC) was established, demonstrating strong alignment between <i>in vitro</i> dissolution and <i>in vivo</i> absorption up to 4 h, with a minor lag time observed. These results further confirmed the likely absorption of BI 894416 in the upper gastrointestinal (GI) tract and the potentially ascending colon. These findings highlight the potential of MED 3D printing to streamline the development of MR formulations in preclinical settings, offering a flexible, efficient, and material-sparing alternative to conventional approaches.

Molecular PharmaceuticsVol. 22(9)
Boehringer Ingelheim (Germany) (DE), China Design Group (China) (CN), Boehringer Ingelheim (Switzerland) (CH), Boehringer Ingelheim (China) (CN), Boehringer Ingelheim (Australia) (AU), Boehringer Ingelheim (United States) (US)
Industry, innovation and infrastructure
Openalex Percentile: Top 81%
3D Printing in Biomedical Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.